Contraceptive Development Research Centers (P50 Clinical Trial Optional)
ID: 357196Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357196

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-HD-26-004.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Contraceptive Development Research Centers (P50 Clinical Trial Optional)" aimed at advancing the development of new and improved contraceptive methods for both men and women. This initiative seeks to establish multidisciplinary Contraceptive Development Research Centers that will conduct laboratory and clinical research, including translational studies to enhance the likelihood of clinical success. The program is particularly focused on late-stage preclinical or clinical development of contraceptive products, encouraging proposals that explore innovative options such as non-steroidal contraceptives and novel delivery mechanisms. Up to $6 million in funding is available for fiscal year 2026, with a project period of up to four years. Interested applicants must submit their proposals by November 13, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-HD-26-004-Full-Announcement.html
    RFA-HD-26-004.html
    The National Institutes of Health (NIH) under the Department of Health and Human Services is releasing a funding opportunity (RFA-HD-26-004) called the Contraceptive Development Research Centers (P50 Clinical Trial Optional). This initiative aims to bolster multidisciplinary efforts in developing new or improved contraceptive methods for men and women. It emphasizes establishing Contraceptive Development Research Centers to support both laboratory and clinical research while including translational studies for effective clinical outcomes. The NIH expects the Center to conduct at least two Contraception Development Research Projects focused on the late-stage preclinical or clinical development of contraceptive products, particularly those showing industrial interest. Applicants are encouraged to submit diverse proposals addressing areas like non-steroidal male and female contraceptives and innovative delivery mechanisms. Funding availability includes up to $6 million for FY 2026 with a project period extending to four years. Eligible organizations include higher education institutions, nonprofits, and government entities. The application deadline is November 13, 2025, with an important emphasis on conforming to the guidelines set forth in the application instructions. The focus on enhancing contraceptive options reflects a commitment to addressing public health needs through innovative research.
    Similar Opportunities
    Biological Testing Facility (X01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Biological Testing Facility (X01 Clinical Trial Not Allowed)" aimed at advancing contraceptive development programs through the provision of specialized services. This funding opportunity announcement (FOA) is designed to support innovative and validated methods that are essential for future clinical development, allowing applicants who may not currently hold NIH funding to apply, although priority may be given to those with existing NIH support. The grant is categorized under Income Security and Social Services, with no cost-sharing or matching requirements, and is open to a diverse range of eligible applicants, including various educational institutions and organizations. Interested parties should note that the application deadline is May 2, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-23-128.html.
    Biological Testing Facility (X01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Biological Testing Facility (X01 Clinical Trial Not Allowed)" aimed at supporting research in the development of non-hormonal contraceptive methods. This grant allows investigators to access the Biological Testing Facility (BTF) for preclinical studies and Investigational Device Exemption (IDE) or Investigational New Drug (IND)-enabling studies, with a focus on advancing contraceptive development to address unintended pregnancies in the U.S. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and foreign entities, with applications due by May 2, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-23-192.html.
    Chemical Screening and Optimization Facility (X01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), is offering a funding opportunity titled "Chemical Screening and Optimization Facility (X01 Clinical Trial Not Allowed)." This initiative aims to support the development of non-hormonal contraceptives and reproductive health products by providing access to a state-of-the-art facility that offers preclinical services, including protein generation, high throughput screening, and drug metabolism studies. The program is designed to facilitate research that leads to safe and effective reproductive health therapies, with a focus on innovation and scientific merit in project proposals. Applications are open from September 3, 2023, with deadlines on October 3 and April 3 annually until 2026. Eligible applicants include various organizations such as higher education institutions, non-profits, and tribal governments. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Planning for Product Development Strategy (R34 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "Planning for Product Development Strategy," aimed at supporting the development of comprehensive strategies for next-generation treatments and preventive methods for HIV and associated complications. The primary objective of this grant is to facilitate the planning activities necessary for submitting an Investigational New Drug (IND) application to the FDA, with a focus on translating innovative research into effective drug products. This funding opportunity is particularly significant as it encourages collaboration among multidisciplinary teams to address critical health challenges related to HIV. Interested applicants can apply starting February 13, 2024, with a total funding amount of $1,000,000 anticipated for 2-3 awards in fiscal year 2025. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-029.html.
    Notice of Intent to Publish a Funding Opportunity Announcement for Improving Uptake and Use of the Dapivirine Vaginal Ring for HIV Prevention (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Funding Opportunity Announcement (FOA) aimed at improving the uptake and use of the dapivirine vaginal ring for HIV prevention. This initiative seeks to advance research on understanding the multilevel facilitators and barriers to the use of the vaginal ring, develop interventions to enhance its uptake and consistent use, and test implementation strategies for optimal delivery. The anticipated funding amount for this grant is up to $500,000, with the FOA expected to be published in Winter 2022 and applications due in Summer 2022. Interested applicants can reach out to Dr. Teri Senn at teri.senn@nih.gov or by phone at 301-761-7852 for further information.
    NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering the P50 Research Center of Excellence Grant Program to support innovative research in substance use and addiction. This program aims to establish multidisciplinary research centers that not only advance scientific knowledge but also serve as national resources for education and outreach within the drug abuse research community. The initiative encourages applications that focus on integrated themes rather than incremental work, with a budget limit of $10 million over five years and a maximum of 25% of direct costs allocated to pilot projects. Interested applicants should note that the submission process requires adherence to specific guidelines, including a Plan for Enhancing Diverse Perspectives (PEDP), and key deadlines extend until November 18, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Notice of Intent to Publish a Funding Opportunity Announcement for Intellectual and Developmental Disabilities Research Centers 2025 (P50 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Intellectual and Developmental Disabilities Research Centers (IDDRCs) in 2025, with a focus on advancing research in the diagnosis, prevention, treatment, and amelioration of intellectual and developmental disabilities (IDD). This initiative aims to foster collaborative research through specialized centers supported by multi-project grant awards under the P50 activity code. The anticipated funding amount for each center is up to $1 million, with the NOFO expected to be published in Summer 2024 and applications due in Fall 2024. Interested applicants should prepare to develop meaningful collaborations and responsive projects, as the estimated award date is set for July 1, 2025.
    Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting proposals for the R21 Exploratory/Developmental Research Grant under the funding opportunity titled "Innovations to Optimize HIV Prevention and Care Continuum Outcomes." This initiative aims to support innovative research that enhances HIV prevention and care strategies by exploring behavioral and social science approaches, new intervention methods, and implementation science, particularly addressing gaps in engagement, adherence, and retention in healthcare services. The grant, with a funding ceiling of $275,000 over two years, emphasizes collaboration with community organizations and the inclusion of diverse populations, aligning with national and global health objectives. Interested applicants can submit their proposals until January 9, 2026, and should direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required) to support innovative research projects in the early stages that can lead to significant advancements in biomedical, behavioral, and clinical research. This funding opportunity requires applicants to propose at least one clinical trial and is aimed at addressing critical gaps in knowledge within the scientific missions of participating NIH Institutes and Centers. Eligible applicants include a diverse range of organizations, such as higher education institutions, nonprofits, and foreign entities, with a total project period limited to two years and a budget of up to $275,000. The application period opens on January 16, 2025, and closes on January 8, 2028; interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Developmental Centers for AIDS Research (P30 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Funding Opportunity Announcement (FOA) for the Developmental Centers for AIDS Research (D-CFAR) program, aimed at enhancing HIV/AIDS research through administrative support and shared resources. This initiative invites applications from eligible institutions to establish D-CFARs that will foster interdisciplinary collaboration and address gaps in research infrastructure, with a focus on supporting early career investigators. Each institution may submit one application, with potential awards totaling up to $1 million annually for a duration of five years, and applications are due by August 4, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-117.html.